Loading clinical trials...
Loading clinical trials...
A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 2)
Conditions
Interventions
Delgocitinib cream
Cream vehicle
Locations
50
Belgium
LEO Investigational Site
Brussels, Belgium
LEO Investigational Site
Edegem, Belgium
LEO Investigational Site
Ghent, Belgium
LEO Investigational Site
Kortrijk, Belgium
LEO Investigational Site
Leuven, Belgium
LEO Investigational Site
Loverval, Belgium
Start Date
May 25, 2021
Primary Completion Date
December 27, 2022
Completion Date
January 6, 2023
Last Updated
April 8, 2025
Lead Sponsor
LEO Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions